NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Diamondjim61,

Up to about 85% of all GBM becomes mesenchymal subtype at progression. IDH1 wild type is associated with mesenchymal genotype and phenotype. Neither mesenchymal or IDH1 wild type was accounted for in this study but they have become known as prognostic indicators in relationship to DC therapies. The 100 longest lived patients have no accounted for individual characteristic that explains their longer survival. Think about this for a minute and maybe things might start to make a little more sense. Almost 90% of patients received DCVax-L and later patients seem to be doing quite a bit better than early ones. Best wishes.